上市公司资料
 
百奥赛图(北京)医药科技股份有限公司 股票代号:  02315
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 集团网址: http://www.biocytogen.com.cn/
损益表
  2024/12
RMB($)
变动 2023/12
RMB($)
2022/12
RMB($)
营业额980,454,00036.761%716,912,000533,881,000
经营溢利/(亏损)72,693,000--(370,129,000)(586,583,000)
特殊项目--------
摊占联营公司及共同控制公司溢利/(亏损)(29,753,000)--(10,027,000)(14,770,000)
税前溢利/(亏损)42,940,000--(380,156,000)(601,353,000)
税项(9,403,000)--(2,796,000)(804,000)
少数股东权益5,000400.000%1,000212,000
股东应占溢利/(亏损)33,542,000--(382,951,000)(601,945,000)
 
净利息收入/(支出)(85,780,000)--(89,686,000)(53,972,000)
折旧与摊销169,181,000-10.949%189,982,000174,099,000
董事酬金8,422,00033.028%6,331,0003,672,000
 
每股盈利/(亏损)(仙)8.000--(96.000)(158.000)
每股派息(仙)0.000--0.0000.000
 
派息比率(%)0.000%------
每股帐面资产净值($)2.0886.129%1.9682.870
主要财务比率
  2024/12
RMB($)
变动 2023/12
RMB($)
2022/12
RMB($)
经营边际利润率(%)7.414%--(51.628)%(109.871)%
利息盈利率(x)1.468------
资产回报率(%)1.379%--(14.591)%(23.594)%
股东资金回报率(%)4.141%--(39.640)%(50.299)%

 

Copyright © 2026 ET Net Limited. All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.